Trinity Life Sciences Institutes a Formal Cell and Gene Therapy Center of Excellence

COE Provides Deep Strategic Expertise and Analytical Capabilities to Support Cell and Gene Therapy Organizations Across the Value Chain

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy (C&GT) Center of Excellence (COE) that supports life sciences companies in successfully commercializing a C&GT asset. The unique challenges and opportunities in commercializing C&GT are markedly different from traditional one-size-fits-all products, requiring innovation and a change in the traditional commercial model.

To enable true commercialization optimization in the C&GT space, there are several areas with C&GT nuances that need to be considered:

  • Operational Model Efficiencies
  • Specialized Manufacturing & Supply Chain Logistics
  • Market Access Complexity
  • Unique Go-To-Market Strategies
  • Patient Centricity
  • Life Cycle Management

Trinity’s C&GT COE provides global partnership to life sciences companies and other service providers in the value chain through advisory services powered by a dedicated team of experts with extensive C&GT commercialization and disease area expertise. Clients are able to leverage expert support and analytical depth, no matter where they are in the commercialization journey. Advisory project examples include:

– Comprehensive situation analysis as a foundation for a gene therapy

– Launch management activities in preparation to commercialize a cell therapy product

– Opportunity evaluation and business development decision support for gene therapies

– Understanding of current market dynamics, potential peak share and value drivers for a novel product

– Modeling of potential Health Care Professionals (HCP) uptake, pricing opportunities and size of the eligible populations for a gene therapy forecast

– And much more

“Trinity is patient first—and every challenge in C&GT commercialization has the added impetus of patients waiting for life-changing therapies,” explains Herman Sanchez, Chief Business Officer at Trinity Life Sciences. “Understanding and resolving those problems have become table stakes with C&GT assets. As these treatments may be curative or first on the market, that work is especially meaningful and impactful.”

“After years of experiencing industry challenges firsthand while commercializing gene therapies, I understand the value of strategic partners who are experienced in C&GT and have supported manufacturers along the challenges commercialization presents,” explained Keren Shani, Executive Director and Head of Cell & Gene Therapy at Trinity Life Sciences. “Trinity launched the C&GT COE to support clients in a uniquely cross-functional way, so that we can share learnings from our depth of exposure and breadth of experience across client organizations and throughout the lifecycle.”

A new white paper, Empowering Cancer Immunotherapy: Unleashing the Potential of NK Cell Therapies in Oncology, delivers an overarching assessment of the Natural Killer (NK) cell therapy space with a background on NK-based technology, current clinical development—and ultimately, the value proposition NK cell therapies hold in order to equip readers with the necessary knowledge to drive informed decision-making and potential investment in the space.

Life sciences executives can access the white paper here.

An on-demand webinar, Gene Therapy Uptake: The Elephant in the Room, evaluates the factors that are unique to forecasting gene therapy markets and discusses what companies need to know to maximize their revenue potential. Among other topics, viewers will hear potential pricing strategies to consider—as well as key market drivers and product factors contributing to gene therapy opportunity.

Life sciences executives can view the webinar here.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy